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Background. Methicillin-resistant S. aureus (MRSA) and Vancomycin-resistant 
enterococci (VRE) are endemic in post-acute care (PAC) settings. We characterize their 
transmission between patients and environment in 6 PAC facilities in SE Michigan.
Methods. In a multicenter prospective observational cohort study we collected 
surveillance cultures of nares, oropharynx, groin, perianal area, wounds, device site(s) 
and 10 environmental sites collected at enrollment, day 14, and every 30 days thereafter 
from 651 newly admitted patients. Pulsed-field gel electrophoresis (PFGE) and PCR 
for SCCmec, agr, and Panton–Valentine leukocidin (pvl) were performed for MRSA. 
PFGE, and vanA/vanB genotyping were performed for VRE.
Results. 386/651 (59%) participants were not colonized with MRSA at baseline, 
had more than 1 follow-up visit and were observed for 15,683 patient-days, over 
which 5,558 patient and 11,108 environmental swabs were collected. Of these 386 
patients, 47 (12%) newly acquired MRSA and had complete strain typing available. 
42% of strains were USA 100 HA-MRSA, and 31% were USA 300 CA-MRSA. 14% 
of strains were non USA 100–1100 strains. For 11/47 (23%), a related MRSA strain 
was isolated from the environment during the previous visit (Figure 1). 24/47 had 
a subsequent follow-up visit. In 13/24 (54%) a related MRSA strain was found in 
the environment on the next visit, suggesting transmission from the patient to the 
environment (Figure 1).
For VRE, PFGE profiles showed high heterogeneity. Among 76 of 296 patients 
(followed for 11,580 days) who newly acquired VRE, a related VRE was found in the 
previous visit in 12% of patients, no VRE was found in the previous visit for 42 (55%), 
and an unrelated strain was present for 33%. In 37 patients for whom a follow-up visit 
was available, 22% had a related VRE strain in the environment on the subsequent visit 
and 27% had a new VRE strain.
Conclusion. New acquisition of VRE was more common than MRSA in this 
PAC population. Using molecular epidemiologic methods in this large prospective 
cohort, we show active, frequent and immediate bi-directional transmission between 
patients and environment. Diminishing environmental contamination has the poten-
tial to reduce MDRO transmission to patients in a setting where MRSA and VRE are 
endemic. 
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Background. Methicillin resistant Staphylococcus aureus (MRSA) has been 
declining over the past decade, but changes in S. aureus overall and the implications 
for trends in antibiotic resistance remain unclear. We determine whether the decline in 
rates of infection by MRSA has been accompanied by changes in rates of infection by 
methicillin susceptible, penicillin resistant S. aureus (MSSA) and penicillin susceptible 
S. aureus (PSSA). We test if these dynamics are associated with specific genetic lineages 
and evaluate gains and losses of resistance at the strain level.
Methods. We conducted a 15 year retrospective observational study at two ter-
tiary care institutions in Boston, MA of 31,589 adult inpatients with S. aureus infec-
tions. Surveillance swabs and duplicate specimens were excluded. We also sequenced 
a sample of contemporary isolates (n = 180) obtained between January 2016 and July 
2016. We determined changes in the annual rates of infection per 1,000 inpatient 
admissions by S. aureus subtype and in the annual mean antibiotic resistance by sub-
type. We performed phylogenetic analysis to generate a population structure and infer 
gain and loss of the genetic determinants of resistance.
Results. Of the 43,954 S.  aureus infections over the study period, 21,779 
were MRSA, 17,565 MSSA and 4,610 PSSA. After multivariate adjustment, 
annual rates of infection by S. aureus declined from to 2014 by 2.9% (95% con-
fidence interval (CI), 1.6%–4.3%), attributable to an annual decline in MRSA 
of 9.1% (95% CI, 6.3%–11.9%) and in MSSA by 2.2% (95% CI, 0.4%–4.0%). 
PSSA increased over this time period by 4.6% (95% CI, 3.0%–6.3%) annually. 
Resistance in S. aureus decreased from 2000 to 2014 by 0.86 antibiotics (95% CI, 
0.81–0.91). By phylogenetic inference, 5/35 MSSA and 2/20 PSSA isolates in the 
common MRSA lineages ST5/USA100 and ST8/USA300 arose from the loss of 
genes conferring resistance.
Conclusion. At two large tertiary care centers in Boston, S. aureus infections have 
decreased in rate and have become more susceptible to antibiotics, with a rise in PSSA 
making penicillin an increasingly viable and important treatment option.
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Background. Providers often must decide whether to empirically treat hospitalized 
patients for MRSA. The results of routine MRSA nares swabs often are available prior to 
clinical culture results, so could conceivably help guide antibiotic selection. However, the 
reported predictive value of nares swabs is mixed. Therefore, we sought to define the pre-
dictive characteristics of MRSA nares swabs for the MRSA status of clinical Staphylococcus 
aureus(SA) isolates at the Minneapolis Veterans Affairs Medical Center (MVAMC).
Methods. We retrospectively reviewed electronic health records (EHRs) of 
599 MVAMC inpatients with a clinical SA isolate between 2013 and 2016. The SA 
isolates were from skin/soft tissue (n = 281), blood (n = 99), respiratory (n = 90), 
urine (n = 62), and bone/joint (n = 27). We recorded each isolate’s MRSA vs. MSSA 
status and the result of the temporally closest MRSA nares swab, then compared 
swab and culture results in relation to culture site and swab-to-culture interval.
Results. Overall, for identifying MRSA among patients with a clinical SA isolate, 
the MRSA nares swab’s sensitivity was 65.1%, specificity 96.2%, positive predictive 
value (PPV) 91.4%, and negative predictive value (NPV) 81.9%. The odds ratio (OR) 
of a positive MRSA nares swab for a MRSA-positive culture was 47.9 (95% confidence 
interval [CI] 25.7–89.2). Exclusion of the 70 nares swabs that were collected > 14 days 
before the clinical isolate increased the NPV to 84.0%, with a corresponding sensitivity 
68.0%, specificity 83.9%, and PPV 90.3%. Test performance varied significantly by cul-
ture site (Table).
Culture Site OR (95% CI) Sens. (%) Spec. (%) PPV (%) NPV (%)
All 47.9 (25.7–89.2) 65.1 96.2 91.4 81.9
Skin/soft tissue59.7 (22.5–158.3) 63.4 97.2 93.0 81.9
Blood 65.9 (13.6–319.9) 95.8 96.9 92.0 85.1
Respiratory 64.1 (13.3–309.5) 73.2 95.9 93.8 81.0
Urine 13.5 (3.7–49.5) 64.3 88.2 81.8 75.0
Bone/joint N/A 20.0 100.0 100.0 84.6
Conclusion. A positive MRSA nares swab greatly increased the odds that a SA 
isolate was MRSA. However, sensitivity and NPV were lower than some prior studies. 
Our findings suggest that, for veterans with a severe infection that might be due to SA, 
a negative MRSA nares screen provides insufficient NPV to allow confident omission 
of empiric MRSA-active antibiotics.
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